Table III.
Characteristics of patients with positive eoc-PET/CT scans after ABVD who were selected for treatment with RT alone (n = 11; included in the current study cohort) vs. salvage chemotherapy with autologous stem cell transplantation (n = 15; not included in the current study cohort)
| Characteristic | RT Alone (n = 11) | Salvage Chemotherapy/ASCT (n = 15) | P |
|---|---|---|---|
| Median Age (Range), years | 25 (20–70) | 28 (20–41) | 0.3 |
| Stage I / Stage II | 0 (0%) / 11 (100%) | 0 (0%) / 15 (100%) | |
| Bulk | 4 (36%) | 4 (27%) | 0.7 |
| Extranodal disease | 1 (9%) | 1 (7%) | 1.0 |
| Median Number of ABVD Cycles (Range) | 6 (4–6) | 6 (4–6) | 0.6 |
| Biopsies Performed | 3 (27%) | 13 (87%) | 0.004 |
| Biopsies Positive | 1 (9% of cohort; 33% of biopsies) | 13 (87% of cohort; 100% of biopsies) | <0.001 |
| Median Final SUVmax (Range) | 4.9 (2.7–11.5) | 9.0 (2.5–20) | 0.02 |
| Median Final MTV (Range), ml | 2.2 (0.1–19) | 14 (1.4–648) | 0.2 |
| Median Final TLG (Range) | 7.1 (0.3–73) | 48 (4.1–4497) | 0.3 |
| Median Final STV (Range), ml | 21 (2.6–236) | 50 (11–883) | 0.04 |
| Median SUVmax Reduction (Range) | 63% (−87–77%) | 26% (−120–68%) | 0.2 |
| Median MTV Reduction (Range) | 99% (83–100%) | 94% (20–98%) | 0.09 |
| Median TLG Reduction (Range) | 99% (88–100%) | 97% (26–99%) | 0.09 |
| Median STV Reduction (Range) | 85% (59–95%) | 83% (−10–90%) | 0.1 |
ABVD = doxorubicin, bleomycin, vinblastine and dacarbazine
ASCT = autologous stem cell transplant
MTV = metabolic tumour volume
RT = radiation therapy
STV = soft tissue volume
SUVmax = maximum standardized uptake value
TLG = total lesion glycolysis